ACS Medicinal Chemistry Letters · 2015 · 65 citations · 15 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryMolecular OncologyCancer EpigeneticsEnzyme InhibitionEpigenetic Regulation In CancerTumor Suppressor GenesChemical Structure-activity RelationshipsCocrystal FormationDna MethyltransferasesLysine Methyltransferase ActivityMethylation ProcessesPharmacological PotencyPotency MeasurementTumor Suppressor Pathways
A lack of useful small molecule tools has precluded thorough interrogation of the biological function of SMYD2, a lysine methyltransferase with known tumor-suppressor substrates. Systematic exploration of the structure-activity relationships of a previously known benzoxazinone compound led to the synthesis of A-893, a potent and selective SMYD2 inhibitor (IC50: 2.8 nM). A cocrystal structure reveals the origin of enhanced potency, and effective suppression of p53K370 methylation is observed in a lung carcinoma (A549) cell line.
15
P M O'Connor, Joany Jackman, I Bae et al. · PubMed · 1997 · 882 citations
Repression of p53 activity by Smyd2-mediated methylation
Jing Huang, Laura Perez-Burgos, Brandon J. Placek et al. · Nature · 2006 · 620 citations
Mark A. Brown, Robert J. Sims, Paul Gottlieb et al. · Molecular Cancer · 2006 · 312 citations · Full text